• 1
    Meador KJ. Cognitive effects of epilepsy and of antiepileptic medications. In: WyllieE, ed. The treatment of epilepsy: principles and practice. 2nd ed. Baltimore: Williams & Wilkins, 1996: 112130.
  • 2
    White HS. Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs. Epilepsia 1997;38(suppl 1):S917.
  • 3
    Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, 600-mg dosages. Neurology 1996;46: 168490.
  • 4
    Privitera M, Fincham R, Penry J, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, 1000-mg dosages. Neurology 1996;46: 167883.
  • 5
    Ben-Menachem E, Henriksen O, Dam M, et al. Double-blind placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996;37: 53943.
  • 6
    Tassinari CA, Michelucci R, Chauvel P, et al. Double-blind placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 1996;37: 7638.
  • 7
    Sharieff M, Viteri C, Ben-Menachem, et al. Double-blind placebo-controlled study of topiramate in patients with refractory seizures. Epilepsy Res 1996;25: 21724.
  • 8
    Sachdeo RC, Glauser TA, Ritter F, et al. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Neurology 1999;52: 18827.
  • 9
    Ritter FJ, Glauser TA, Sachdeo RC, et al. Long-term experience with topiramate in Lennox-Gastaut syndrome. Epilepsia 1998;39(suppl 2):A2.
  • 10
    Biton V, Montouris GD, Ritter F. A study of topiramate in primary generalized tonic-clonic seizures. Neurology 1999;52: 13307.
  • 11
    Rosenfeld WE. Topiramate: a review of preclinical, pharmacokinetic, and clinical data. Clin Ther 1997;19: 1294308.
  • 12
    Privitera M. Long-term efficacy and safety of topiramate. Epilepsia 1995;36(suppl3):A152.
  • 13
    Ben-Menachem E. Long-term follow-up of patients treated with topiramate for partial seizures. Epilepsia 1995;36(suppl 3):A152.
  • 14
    Kaufman DW, Kelly JP, Anderson T, et al. Evaluation of case reportsof aplastic anemia among patients treated with felbamate. Epilepsia 1997;38: 12659.
  • 15
    Tatum WO IV, Moore DB, Stecker MM, et al. Ventricular asystole during vagus nerve stimulation for epilepsy in humans. Neurology 1999;52: 12679.
  • 16
    Kanner AM, Faught E, French JA, Tatum WO, et al. Psychiatric adverse events caused by topiramate and lamotrigine: a post-marketing prevalence and risk factor study. Epilepsia 2000;41(Suppl 7): 169A.
  • 17
    Kalviainen R, Aikia M, Riekkinen PJ. Cognitive adverse effects of antiepileptic drugS.CNS Drugs1996;6: 35868.
  • 18
    NiuMT, Salive ME, Ellenberg SS. Post-marketing surveillance for adverse events after vaccination: the national Vaccine Adverse Event Reporting System (VAERS). MEDWATCH 1998;00: 000.
  • 19
    Martin R, Kuzniecky R, Ho S, et al. Cognitive effects of topiramate, gabapentin, andlamotrigine in healthy young adults. Neurology 1999;52: 3217.
  • 20
    Sharief MW, Sander JWAS, Shorvon SD. Long term treatment with topiramate in refractory partial epilepsy: a two year follow-up study. Seizure 1992;1(suppl A):747.
  • 21
    Kamin M & Abou-Khalil, and theYOL Topiramate Study Team. Long-term efficacy in anopen-label trial of topiramate. Epilepsia 1996;37(suppl 5):168.
  • 22
    Walker MC & Sander JW. Topiramate: a new antiepileptic drug for refractory epilepsy. Seizure 1996;5: 199203.
  • 23
    Sachdeo RC, Reife RA, Lim P, et al. Topiramate monotherapy for partial onset seizures. Epilepsia 1997;38: 2635.
  • 24
    Product Monograph. Ortho-McNeil Pharmaceutical.
  • 25
    Shorvon SD. Safety of topiramate: adverse events and relationship to dosing. Epilepsia 1996;37(suppl 2):S1822.
  • 26
    Rosenfeld WE, Liao S, Kramer LD, et al. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy duringmonotherapy and concomitant therapy. Epilepsia 1997;38: 32433.
  • 27
    Meador KJ, Loring DW, Moore EE, et al. Comparative cognitive effects of phenobarbital, phenytoin, and valproate in healthy subjects. Neurology 1995;45: 14949.
  • 28
    Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalizedtonic-clonic seizures. N Engl J Med 1985;313: 14551.
  • 29
    Privitera M. Long-term cognitive effects of topiramate. Epilepsia 1995;36(suppl 3):A152.
  • 30
    Burton L & Harden CL. Effects of topiramate on attention over time. Epilepsy Res 1997;27: 2932.
  • 31
    Marson AG, Kadir ZA, Hutton JL, et al. The new antiepileptic drugs:a systemic review of their efficacy and tolerability. Epilepsia 1997;38: 85980.
  • 32
    Edwards KR & Kamin M, Topiramate TPS-TR Study Group. The beneficial effect of slowing the initial titration rate of topiramate. Neurology 1997;48(suppl 2):A39.
  • 33
    Meador KJ. Assessing cognitive effects of a new AED without the bias of practice effects. Epilepsia 1997;38(suppl 3):S60.
  • 34
    Aldenkamp AP, Baker G, Mulder OG, et al. A multicenter randomized clinical study to evaluate the effect of cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial onset seizures. Epilepsia 2000;41: 116778.
  • 35
    Kellett MW, Smith DF, Stockton PA, et al. Topiramate in clinical practice: first year's licensing experience in a specialist epilepsy clinic. J Neurol Neurosurg Psychiatry 1999;66: 75963.